SC 13G/A | 2023-02-09 | VANGUARD GROUP INC | PMV Pharmaceuticals, Inc. | 2,753,606 | 6.0% | EDGAR |
SC 13G/A | 2023-01-31 | BlackRock Inc. | PMV Pharmaceuticals, Inc. | 3,451,367 | 7.6% | EDGAR |
SC 13G/A | 2023-01-25 | JPMORGAN CHASE & CO | PMV Pharmaceuticals, Inc. | 4,004,767 | 8.7% | EDGAR |
SC 13G/A | 2023-01-24 | Cowen Financial Products LLC | PMV Pharmaceuticals, Inc. | 1,500,326 | 3.3% | EDGAR |
SC 13G | 2022-07-11 | STATE STREET CORP | PMV Pharmaceuticals, Inc. | - | 11.4% | EDGAR |
SC 13G/A | 2022-07-07 | JPMORGAN CHASE & CO | PMV Pharmaceuticals, Inc. | 4,585,459 | 10.0% | EDGAR |
SC 13G | 2022-06-17 | CITADEL ADVISORS LLC | PMV Pharmaceuticals, Inc. | - | 3.1% | EDGAR |
SC 13D/A | 2022-04-01 | ORBIMED ADVISORS LLC | PMV Pharmaceuticals, Inc. | 6,589,330 | 14.5% | EDGAR |
SC 13G/A | 2022-02-14 | Nextech V Oncology S.C.S., SICAV-SIF | PMV Pharmaceuticals, Inc. | 1,385,807 | 3.1% | EDGAR |
SC 13G/A | 2022-02-14 | VIKING GLOBAL INVESTORS LP | PMV Pharmaceuticals, Inc. | 1,790,284 | 3.9% | EDGAR |
SC 13G/A | 2022-02-14 | INTERWEST PARTNERS X LP | PMV Pharmaceuticals, Inc. | 3,234,911 | 7.1% | EDGAR |
SC 13G/A | 2022-02-14 | Euclidean Capital LLC | PMV Pharmaceuticals, Inc. | 2,336,909 | 5.1% | EDGAR |
SC 13G/A | 2022-02-14 | Boxer Capital, LLC | PMV Pharmaceuticals, Inc. | 2,838,236 | 6.3% | EDGAR |
SC 13G | 2022-02-14 | RTW INVESTMENTS, LP | PMV Pharmaceuticals, Inc. | 2,980,960 | 6.6% | EDGAR |
SC 13G/A | 2022-02-11 | Avoro Capital Advisors LLC | PMV Pharmaceuticals, Inc. | 1,465,000 | 3.2% | EDGAR |
SC 13G | 2022-02-10 | VANGUARD GROUP INC | PMV Pharmaceuticals, Inc. | 2,647,946 | 5.8% | EDGAR |
SC 13G | 2022-02-04 | BlackRock Inc. | PMV Pharmaceuticals, Inc. | 2,539,824 | 5.6% | EDGAR |
SC 13G | 2022-01-26 | JPMORGAN CHASE & CO | PMV Pharmaceuticals, Inc. | 3,166,450 | 6.9% | EDGAR |
SC 13G | 2022-01-19 | Cowen Financial Products LLC | PMV Pharmaceuticals, Inc. | 2,300,000 | 5.1% | EDGAR |
SC 13G/A | 2021-10-18 | Euclidean Capital LLC | PMV Pharmaceuticals, Inc. | 2,455,199 | 5.4% | EDGAR |